22 studies found for:    AMG145 | Phase 3
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
Condition: Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Interventions: Drug: Atorvastatin;   Biological: Evolocumab;   Other: Placebo to Evolocumab
2 Completed
Has Results
Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen
Conditions: Primary Hypercholesterolemia;   Mixed Dyslipidemia
Interventions: Biological: Evolocumab Pre-filled Syringe;   Biological: Evolocumab AI/pen
3 Completed
Has Results
Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
Conditions: Primary Hypercholesterolemia;   Mixed Dyslipidemia
Interventions: Biological: Evolocumab AMD;   Biological: Evolocumab AI/pen
4 Recruiting Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Condition: Hypercholesterolemia
Interventions: Biological: evolocumab (AMG 145);   Other: Low Density Lipoprotein Cholesterol (LDL-C) Apheresis
5 Not yet recruiting Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).
Condition: Familial Hypercholesterolemia
Intervention: Biological: evolocumab (AMG 145)
6 Active, not recruiting Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
Condition: Severe Familial Hypercholesterolemia
Intervention: Biological: Evolocumab (AMG145)
7 Not yet recruiting Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4
Condition: Hypercholesterolemia
Interventions: Biological: Evolocumab;   Drug: Ezetimibe
8 Completed
Has Results
Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
Condition: Homozygous Familial Hypercholesterolemia
Interventions: Biological: Evolocumab;   Drug: Placebo
9 Completed
Has Results
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
Condition: Hyperlipidemia
Interventions: Biological: Evolocumab;   Drug: Ezetimibe;   Biological: Placebo to Evolocumab;   Other: Placebo to Ezetimibe
10 Completed
Has Results
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
Condition: Hyperlipidemia
Interventions: Biological: Evolocumab;   Drug: Placebo to Evolocumab;   Drug: Ezetimibe;   Drug: Placebo to Ezetimibe
11 Completed
Has Results
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
Condition: Hyperlipidemia
Interventions: Biological: Evolocumab;   Drug: Placebo
12 Completed
Has Results
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
Condition: Hypercholesterolemia
Interventions: Biological: Evolocumab;   Biological: Placebo;   Drug: Atorvastatin;   Drug: Ezetimibe;   Other: Diet Only
13 Completed
Has Results
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
Condition: Hyperlipidemia
Interventions: Biological: Evolocumab;   Drug: Ezetimibe;   Drug: Placebo to Evolocumab;   Drug: Placebo to Ezetimibe;   Drug: Atorvastatin;   Drug: Rosuvastatin;   Drug: Simvastatin
14 Active, not recruiting GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
Condition: Hypercholesterolemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo
15 Active, not recruiting Open Label Study of Long Term Evaluation Against LDL-C Trial-2
Condition: Hyperlipidemia and Mixed Dyslipidemia
Interventions: Biological: evolocumab (AMG 145) and standard of care;   Other: Standard of care
16 Not yet recruiting A Double-blind, Randomized Study in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia
Condition: Diabetes, Hyperlipidemia, Mixed Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Drug: Atorvastatin;   Other: Placebo
17 Completed Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
Condition: Primary Hyperlipidemia and Mixed Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Drug: Atorvastatin;   Drug: Placebo
18 Enrolling by invitation Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab
Condition: Hypercholesterolemia
Intervention: Biological: Evolocumab
19 Active, not recruiting Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Condition: Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
20 Active, not recruiting Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
Condition: Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Indicates status has not been verified in more than two years